Top

Diagnostic Pathology

Published in:

Open Access 01-12-2015 | Research

ITPKA expression is a novel prognostic factor in hepatocellular carcinoma

Authors: Jianbiao Li, Ying-Hui Zhu, Pinzhu Huang, Baozhu Zhang, Jian Sun, Xin-Yuan Guan

Published in: Diagnostic Pathology | Issue 1/2015

Abstract

Background

Inositol-1,4,5-trisphosphate-3-kinase-A (ITPKA) has recently been found to be implicated in the tumor progression of various cancers. However, the expression and the prognostic value of ITPKA in hepatocellular carcinoma (HCC) remains unexplored. The aim of this study is to investigate the clinical significance of ITPKA expression in HCC.

Methods

We determined the expression level of ITPKA in 135 cases of HCC tissues and the matched adjacent nontumorous tissues by quantitative real-time RT-PCR. The correlation between ITPKA expression and prognosis of HCC patients was further evaluated by univariate and multivariate analysis. Multivariate analysis of the prognostic factors was performed with Cox proportional hazards model.

Results

Up-regulation of ITPKA occurred in 48.9 % of primary HCCs compared with their nontumor counterparts (P < 0.001). In addition, high expression of ITPKA was significantly associated with vascular invasion (P = 0.001) and TNM stage (P = 0.005). Kaplan–Meier analysis showed that the 5-year overall survival (OS) and relapse-free survival (RFS) rate in the group with high expression of ITPKA is poorer than that in low expression group (32.2 and 26.8 % versus 59.2 and 57.7 %). Univariate and multivariate analyses revealed that ITPKA was an independent prognostic factor for OS and RFS. Moreover, Stratified analysis revealed that its prognostic significance still existed within the subgroup of patients with early clinical stage (TNM stage I) or normal serum AFP level (≤25 μg/L).

Conclusion

Our data indicated that ITPKA expression was significantly up-regulated in HCC and could serve as a potential novel prognostic biomarker for HCC patients after surgery.

Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25(2):143–54. doi:10.1055/s-2005-871194.PubMedCrossRef

Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4(7):424–32. doi:10.1038/ncponc0844.PubMedCrossRef

Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl. 2004;10(2 Suppl 1):S39–45. doi:10.1002/lt.20040.PubMedCrossRef

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef

Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology. 2011;80(3–4):167–74. doi:10.1159/000327591.PubMedCrossRef

Vanweyenberg V, Communi D, D'Santos CS, Erneux C. Tissue- and cell-specific expression of Ins(1,4,5)P3 3-kinase isoenzymes. Biochem J. 1995;306(Pt 2):429–35.PubMedCentralPubMed

Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361(6410):315–25. doi:10.1038/361315a0.PubMedCrossRef

Shears SB. How versatile are inositol phosphate kinases? Biochem J. 2004;377(Pt 2):265–80. doi:10.1042/BJ20031428.PubMedCentralPubMedCrossRef

Johnson HW, Schell MJ. Neuronal IP3 3-kinase is an F-actin-bundling protein: role in dendritic targeting and regulation of spine morphology. Mol Biol Cell. 2009;20(24):5166–80. doi:10.1091/mbc.E09-01-0083.PubMedCentralPubMedCrossRef

10.

Kato H, Uzawa K, Onda T, Kato Y, Saito K, Nakashima D, et al. Down-regulation of 1D-myo-inositol 1,4,5-trisphosphate 3-kinase A protein expression in oral squamous cell carcinoma. Int J Oncol. 2006;28(4):873–81.PubMed

11.

Windhorst S, Kalinina T, Schmid K, Blechner C, Kriebitzsch N, Hinsch R, et al. Functional role of inositol-1,4,5-trisphosphate-3-kinase-A for motility of malignant transformed cells. Int J Cancer. 2011;129(6):1300–9. doi:10.1002/ijc.25782.PubMedCrossRef

12.

Liu Q, Zhao S, Su PF, Yu S. Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma. BMC Syst Biol. 2013;7 Suppl 5:S7. doi:10.1186/1752-0509-7-S5-S7.PubMedCrossRef

13.

Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. doi:10.1186/1479-5876-9-166.PubMedCentralPubMedCrossRef

14.

Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol. 2003;39(2):215–21.PubMedCrossRef

15.

Irvine RF, Lloyd-Burton SM, Yu JC, Letcher AJ, Schell MJ. The regulation and function of inositol 1,4,5-trisphosphate 3-kinases. Adv Enzyme Regul. 2006;46:314–23. doi:10.1016/j.advenzreg.2006.01.009.PubMedCentralPubMedCrossRef

16.

Erneux C, Govaerts C, Communi D, Pesesse X. The diversity and possible functions of the inositol polyphosphate 5-phosphatases. Biochim Biophys Acta. 1998;1436(1–2):185–99.PubMedCrossRef

17.

Windhorst S, Fliegert R, Blechner C, Mollmann K, Hosseini Z, Gunther T, et al. Inositol 1,4,5-trisphosphate 3-kinase-A is a new cell motility-promoting protein that increases the metastatic potential of tumor cells by two functional activities. J Biol Chem. 2010;285(8):5541–54. doi:10.1074/jbc.M109.047050.PubMedCentralPubMedCrossRef

18.

Taylor CW, Thorn P. Calcium signalling: IP3 rises again…and again. Curr Biol. 2001;11(9):R352–5.PubMedCrossRef

19.

Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011;11(8):609–18. doi:10.1038/nrc3105.PubMedCrossRef

20.

Hermosura MC, Takeuchi H, Fleig A, Riley AM, Potter BV, Hirata M, et al. InsP4 facilitates store-operated calcium influx by inhibition of InsP3 5-phosphatase. Nature. 2000;408(6813):735–40. doi:10.1038/35047115.PubMedCrossRef

21.

Irvine R. Inositol phosphates: Does IP(4) run a protection racket? Curr Biol. 2001;11(5):R172–4.PubMedCrossRef

22.

Kim IH, Park SK, Hong ST, Jo YS, Kim EJ, Park EH, et al. Inositol 1,4,5-trisphosphate 3-kinase a functions as a scaffold for synaptic Rac signaling. J Neurosci. 2009;29(44):14039–49. doi:10.1523/JNEUROSCI.2483-09.2009.PubMedCentralPubMedCrossRef

23.

Windhorst S, Blechner C, Lin HY, Elling C, Nalaskowski M, Kirchberger T, et al. Ins(1,4,5)P3 3-kinase-A overexpression induces cytoskeletal reorganization via a kinase-independent mechanism. Biochem J. 2008;414(3):407–17. doi:10.1042/BJ20080630.PubMedCrossRef

24.

Seeds AM, Sandquist JC, Spana EP, York JD. A molecular basis for inositol polyphosphate synthesis in Drosophila melanogaster. J Biol Chem. 2004;279(45):47222–32. doi:10.1074/jbc.M408295200.PubMedCrossRef

25.

Molleman A, Hoiting B, Duin M, van den Akker J, Nelemans A, Den Hertog A. Potassium channels regulated by inositol 1,3,4,5-tetrakisphosphate and internal calcium in DDT1 MF-2 smooth muscle cells. J Biol Chem. 1991;266(9):5658–63.PubMed

26.

Morris AP, Gallacher DV, Irvine RF, Petersen OH. Synergism of inositol trisphosphate and tetrakisphosphate in activating Ca2 + −dependent K+ channels. Nature. 1987;330(6149):653–5. doi:10.1038/330653a0.PubMedCrossRef

27.

Cullen PJ, Hsuan JJ, Truong O, Letcher AJ, Jackson TR, Dawson AP, et al. Identification of a specific Ins(1,3,4,5)P4-binding protein as a member of the GAP1 family. Nature. 1995;376(6540):527–30. doi:10.1038/376527a0.PubMedCrossRef

28.

Stokes AJ, Shimoda LM, Lee JW, Rillero C, Chang YT, Turner H. Fcepsilon RI control of Ras via inositol (1,4,5) trisphosphate 3-kinase and inositol tetrakisphosphate. Cell Signal. 2006;18(5):640–51. doi:10.1016/j.cellsig.2005.06.003.PubMedCrossRef

29.

Marechal Y, Pesesse X, Jia Y, Pouillon V, Perez-Morga D, Daniel J, et al. Inositol 1,3,4,5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells. Proc Natl Acad Sci U S A. 2007;104(35):13978–83. doi:10.1073/pnas.0704312104.PubMedCentralPubMedCrossRef

30.

Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40(3):667–76. doi:10.1002/hep.20375.PubMedCrossRef

31.

Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S108–12.PubMedCrossRef

32.

Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1–2):19–26. 10.1016/j.cca.2008.05.010.PubMedCrossRef

33.

Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130(9):497–513. doi:10.1007/s00432-004-0572-9.PubMedCrossRef

Title: ITPKA expression is a novel prognostic factor in hepatocellular carcinoma
Authors: Jianbiao Li
Ying-Hui Zhu
Pinzhu Huang
Baozhu Zhang
Jian Sun
Xin-Yuan Guan
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-015-0374-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ITPKA expression is a novel prognostic factor in hepatocellular carcinoma

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

A critical role of mir-199a in the cell biological behaviors of colorectal cancer

Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential

CK19 is a sensitive marker for yolk sac tumours of the testis

Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis

MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients

Primary Kaposi’s sarcoma of the heart in non-immunodeficient patient: case report and literature review